MannKind slides after halting late-stage trial of MNKD-101 for lung disease

MannKind Corporation (MNKD) saw a stock decline after the announcement that it would discontinue its trial testing MNKD-101, a nebulized form of clofazimine intended for treating refractory nontuberculous mycobacterial lung disease. The stock fell by 10% in premarket trading. During ...